Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2A Dose Escalation Study of LAM561 in Adult Patients With Advanced Solid Tumours Including Malignant Glioma

NCT01792310 is registered in ClinicalTrials.gov with Laminar Pharmaceuticals as lead sponsor.

NCT NCT01792310
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01792310 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2A Dose Escalation Study of LAM561 in Adult Patients With Advanced Solid Tumours Including Malignant Glioma
Lead sponsor
Laminar Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2013
Completion date
September 30, 2016
Enrollment
54 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

glioma, other solid tumours